Cigna Posts Higher 3Q Profit, Revenue as Evernorth Business Continues to Grow
By Connor Hart
Cigna Group logged higher profit and revenue in the third quarter, boosted by continued strength in its pharmacy-benefit business Evernorth.
The healthcare company on Thursday posted a profit of $1.87 billion, or $6.98 a share, for its three months ended Sept. 30, compared with $739 million, or $2.63 a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were $7.83, ahead of the $7.64 forecast by analysts, according to FactSet.
Revenue rose 9.5% to $69.75 billion. Wall Street had modeled $67.58 billion.
The Bloomfield, Conn., company attributed its higher top line largely to its Evernorth Health Services. Adjusted revenue in Evernorth--which includes pharmacy benefit services and specialty and care services--jumped 15%.
The gain was partially offset by an 18% decline in adjusted revenue in Cigna's namesake segment. Cigna Healthcare, which provides medical plans, included Medicare and related businesses until the company divested them in March.
For the year, Cigna backed its outlook for adjusted earnings of at least $29.60 a share.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
October 30, 2025 06:32 ET (10:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States